Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects

References

• U.S. Food and Drug Administration [website]. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Accessed 625, 2018.
   Google Scholar
• Dijk S, Lok P. NICE rejects cannabidiol for two types of treatment resistant epilepsy in children. BMJ. 2019;366:l5280. doi:10.1136/bmj.l528031444166
   PubMed Web of Science ®Google Scholar
• GW Pharmaceuticals. GW pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy. Accessed 923, 2019.
   Google Scholar
• Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia. 2014;55(6):783–786. doi:10.1111/epi.2014.55.issue-624854149
   PubMed Web of Science ®Google Scholar
• Treister-Goltzman Y, Freud T, Press Y, Peleg R. Trends in publications on medical cannabis from the year 2000. Popul Health Manag. 2019;22(4):362–368. doi:10.1089/pop.2018.011330300079
   PubMed Web of Science ®Google Scholar
• Klein BD, Jacobson CA, Metcalf CS, et al. Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP). Neurochem Res. 2017;42(7):1939–1948. doi:10.1007/s11064-017-2287-828478594
   PubMed Web of Science ®Google Scholar
• Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;13(6):CD009270.
   Google Scholar
• Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;5(3):CD009270.
   Google Scholar
• Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151–165.31332738
   PubMed Web of Science ®Google Scholar
• Hill AJ, Williams CM, Whalley BJ, Stephens GJ. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther. 2012;133(1):79–97. doi:10.1016/j.pharmthera.2011.09.00221924288
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Gaoni Y. A total synthesis of dl-Δ1-tetrahydrocannabinol, the active constituent of hashish”. J Am Chem Soc. 1964;87(14):3273–3275. doi:10.1021/ja01092a065
   Web of Science ®Google Scholar
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561–564. doi:10.1038/346561a02165569
   PubMed Web of Science ®Google Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61–65. doi:10.1038/365061a07689702
   PubMed Web of Science ®Google Scholar
• Cheer JF, Hurd YL. A new dawn in cannabinoid neurobiology: the road from molecules to therapeutic discoveries. Neuropharmacol. 2017;124:1–2. doi:10.1016/j.neuropharm.2017.07.004
   Web of Science ®Google Scholar
• McPartland JM, Duncan M, Di Marzo V, Pertwee RG. Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172(3):737–753. doi:10.1111/bph.1294425257544
   PubMed Web of Science ®Google Scholar
• Olmo IG, Ferreira-Vieira TH, Ribeiro FM. Dissecting the signaling pathways involved in the crosstalk between metabotropic glutamate 5 and cannabinoid type 1 receptors. Mol Pharmacol. 2016;90(5):609–619. doi:10.1124/mol.116.10437227338080
   PubMed Web of Science ®Google Scholar
• Katona I. Cannabis and endocannabinoid signaling in epilepsy. Handb Exp Pharmacol. 2015;231:285–316.26408165
   PubMedGoogle Scholar
• Ruehle S, Remmers F, Romo-Parra H, et al. Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J Neurosci. 2013;33(25):10264–10277. doi:10.1523/JNEUROSCI.4171-12.201323785142
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215. doi:10.1038/sj.bjp.070744217828291
   PubMed Web of Science ®Google Scholar
• Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–4805. doi:10.1111/bph.1325026218440
   PubMed Web of Science ®Google Scholar
• Ryberg E, Larsson N, Sjögren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092–1101. doi:10.1038/sj.bjp.070746017876302
   PubMed Web of Science ®Google Scholar
• Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699–730. doi:10.1007/s13311-015-0377-326264914
   PubMed Web of Science ®Google Scholar
• Franco V, Perucca E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. Drugs. 2019;79(13):1435–1454. doi:10.1007/s40265-019-01171-431372958
   PubMed Web of Science ®Google Scholar
• Lupica CR, Hu Y, Devinsky O, Hoffman AF. Cannabinoids as hippocampal network administrators. Neuropharmacol. 2017;124:25–37. doi:10.1016/j.neuropharm.2017.04.003
   PubMed Web of Science ®Google Scholar
• Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors. Pharmacol Res. 2017;119:358–370. doi:10.1016/j.phrs.2017.02.02228249817
   PubMed Web of Science ®Google Scholar
• Ruffolo G, Cifelli P, Roseti C, et al. A novel GABAergic dysfunction in human dravet syndrome. Epilepsia. 2018;59(11):2106–2117. doi:10.1111/epi.2018.59.issue-1130306542
   PubMed Web of Science ®Google Scholar
• Ghovanloo MR, Shuart NG, Mezeyova J, Dean RA, Ruben PC, Goodchild SJ. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J Biol Chem. 2018;293(43):16546–16558. doi:10.1074/jbc.RA118.00492930219789
   PubMed Web of Science ®Google Scholar
• Patel RR, Barbosa C, Brustovetsky T, Brustovetsky N, Cummins TR. Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol. Brain. 2016;139(Pt 8):2164–2181. doi:10.1093/brain/aww12927267376
   PubMed Web of Science ®Google Scholar
• McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA. Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol. 2008;73(2):441–450. doi:10.1124/mol.107.04186317965195
   PubMed Web of Science ®Google Scholar
• Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci. 2003;23(4):1398–1405. doi:10.1523/JNEUROSCI.23-04-01398.200312598628
   PubMed Web of Science ®Google Scholar
• Epidiolex^® (Cannabidiol) Oral Solution [Prescribing Information]. Carlsbad, CA:Greenwich Biosciences, Inc. 2018.
   Google Scholar
• Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053–1067. doi:10.1007/s40263-018-0578-530374683
   PubMed Web of Science ®Google Scholar
• Birnbaum AK, Karanam A, Marino SE, et al. Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019;60(8):1586–1592. doi:10.1111/epi.v60.831247132
   PubMed Web of Science ®Google Scholar
• Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7(2):61–76. doi:10.14581/jer.1701229344464
   PubMedGoogle Scholar
• Taylor L, Crockett J, Tayo B, Morrison G. A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of Cannabidiol (CBD) in subjects with mild to severe hepatic impairment. J Clin Pharmacol. 2019;59(8):1110–1119. doi:10.1002/jcph.v59.830921490
   PubMed Web of Science ®Google Scholar
• Devinsky O, Patel AD, Thiele EA, GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in dravet syndrome. Neurology. 2018;90(14):e1204–e1211. doi:10.1212/WNL.000000000000525429540584
   PubMed Web of Science ®Google Scholar
• Wheless JW, Dlugos D, Miller I, INS011-14-029 Study Investigators. Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy. CNS Drugs. 2019;33(6):593–604. doi:10.1007/s40263-019-00624-431049885
   PubMed Web of Science ®Google Scholar
• Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246–1251. doi:10.1111/epi.1306026114620
   PubMed Web of Science ®Google Scholar
• GW Research Ltd. A randomized controlled trial to investigate possible drug-drug interactions between clobazam and cannabidiol. ClinicaTrials.gov identifier: NCT02565108 Available from: https://clinicaltrials.gov/ct2/show/NCT02565108?term=NCT02565108&draw=2&rank=1. Accessed 1028, 2019.
   Google Scholar
• Morrison G, Crockett J, Blakey G, Sommerville K, Phase A. 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019;8:1009–1031. doi:10.1002/cpdd.66530791225
   PubMed Web of Science ®Google Scholar
• Anderson LL, Absalom NL, Abelev SV, et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia. 2019;60:2224–2234. doi:10.1111/epi.1635531625159
   PubMed Web of Science ®Google Scholar
• Diacomit^® (Stiripentol) Capsule [Prescribing Information]. Beauvais, France:Biocodex, 2018.
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–1592. doi:10.1111/epi.2017.58.issue-928782097
   PubMed Web of Science ®Google Scholar
• Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60(7):e74–e77. doi:10.1111/epi.1607131211851
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften. 1978;65:174–179. doi:10.1007/BF00450585351429
   PubMed Web of Science ®Google Scholar
• Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology. 1980;21:175–185. doi:10.1159/0001374307413719
   PubMed Web of Science ®Google Scholar
• Ames FR, Cridland S. Anticonvulsant effect of cannabidiol. S Afr Med J. 1985;69:14.
   Web of Science ®Google Scholar
• Trembly B, Sherman M Double-blind clinical study of cannabidiol as a secondary anticonvulsant. Proceedings of: marijuana ’90 international conference on cannabis and cannabinoids; 1990 July 8–11; Kolympari, Crete. International Association for Cannabinoid Medicines; 1990: 5. doi:10.1099/00221287-136-2-327
   Google Scholar
• Devinsky O, Cross JH, Laux L, Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376(21):2011–2020. doi:10.1056/NEJMoa161161828538134
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Brigo F, Trinka E, et al. Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs. 2018;78(17):1791–1804. doi:10.1007/s40265-018-0992-530390221
   PubMed Web of Science ®Google Scholar
• GW Research Ltd. A study to investigate the efficacy and safety of cannabidiol (GWP42003-P) in children and young adults with dravet syndrome. ClinicalTrials.gov identifier: NCT02224703. Available from: https://clinicaltrials.gov/ct2/show/NCT02224703?term=GWPCARE+2&cond=Dravet&draw=2&rank=1. Accessed 1028, 2019.
   Google Scholar
• Devinsky O, Patel AD, Cross JH, GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the lennox-gastaut syndrome. N Engl J Med. 2018;378(20):1888–1897. doi:10.1056/NEJMoa171463129768152
   PubMed Web of Science ®Google Scholar
• GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with lennox-gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2018;391(10125):1085–1096. doi:10.1016/S0140-6736(18)30136-329395273
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Trinka E, Russo E, et al. Cannabidiol as adjunctive treatment of seizures associated with lennox-gastaut syndrome and dravet syndrome. Drugs Today (Barc). 2019;55(3):177–196. doi:10.1358/dot.2019.55.3.290924830938373
   PubMed Web of Science ®Google Scholar
• Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with dravet syndrome: an open-Label extension trial. Epilepsia. 2019;60(2):294–302. doi:10.1111/epi.2019.60.issue-230582156
   PubMed Web of Science ®Google Scholar
• Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, et al. Cannabidiol in patients with lennox-gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60(3):419–428. doi:10.1111/epi.2019.60.issue-330740695
   PubMed Web of Science ®Google Scholar
• Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278. doi:10.1016/S1474-4422(15)00379-826724101
   PubMed Web of Science ®Google Scholar
• Mandelbaum DE. Cannabidiol in patients with treatment-resistant epilepsy. Lancet Neurol. 2016;15(6):544–545. doi:10.1016/S1474-4422(16)00122-8
   Web of Science ®Google Scholar
• Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;377(7):699.
   Web of Science ®Google Scholar
• Thiele EA, Devinsky O, Checketts D, Knappertz V Cannabidiol (CBD) treatment responders analysis in patients with lennox– gastaut syndrome (LGS) on and off clobazam (CLB) [abstract no.1.436]. The American Epilepsy Society Annual Meeting; 1–5 Dec 2017; Washington, DC Available from: https://www.aesne t.org/meeti ngs_event s/annua l_meeti ng_abstr acts/view/381224. Accessed 10, 2019.
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program. Epilepsy Behav. 2019;98(Pt A):201–206. doi:10.1016/j.yebeh.2019.07.00831382177
   PubMed Web of Science ®Google Scholar
• Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617–1624. doi:10.1111/epi.2016.57.issue-1027696387
   PubMed Web of Science ®Google Scholar
• GW Research Ltd. A randomized controlled trial of cannabidiol (GWP42003-P, CBD) for seizures in tuberous sclerosis complex (GWPCARE6). ClinicalTrial.gov Identifier: NCT02544763. Available from: https://clinicaltrials.gov/ct2/show/NCT02544763?term=GWPCARE6&draw=2&rank=1. Accessed 1029, 2019.
   Google Scholar
• GW Pharmaceuticals. GW pharmaceuticals reports positive phase 3 pivotal trial results for EPIDIOLEX^® (cannabidiol) Oral solution in patients with seizures associated with tuberous sclerosis complex. Accessed 56, 2019.
   Google Scholar
• Devinsky O, Verducci C, Thiele EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and aicardi, Dup15q, and doose syndromes. Epilepsy Behav. 2018;86:131–137. doi:10.1016/j.yebeh.2018.05.01330006259
   PubMed Web of Science ®Google Scholar
• Martin RC, Gaston TE, Thompson M, et al. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy Behav. 2019;97:105–110. doi:10.1016/j.yebeh.2019.04.04431220785
   PubMed Web of Science ®Google Scholar
• De Caro C, Leo A, Citraro R, et al. The potential role of cannabinoids in epilepsy treatment. Expert Rev Neurother. 2017;17:1069–1079. doi:10.1080/14737175.2017.137301928845714
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791–802. doi:10.1111/epi.2014.55.issue-624854329
   PubMed Web of Science ®Google Scholar
• Morano A, Cifelli P, Nencini P, et al. Cannabis in epilepsy: from clinical practice to basic research focusing on the possible role of cannabidivarin. Epilepsia Open. 2016;1:145–151. doi:10.1002/epi4.1201529588939
   PubMedGoogle Scholar
• Greco M, Varriale G, Coppola G, Operto F, Verrotti A, Iezzi ML. Investigational small molecules in phase II clinical trials for the treatment of epilepsy. Expert Opin Investig Drugs. 2018;27(12):971–979. doi:10.1080/13543784.2018.1543398
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58:181–221. doi:10.1111/epi.1363428111749
   PubMed Web of Science ®Google Scholar
• GW Research Ltd. A study of GWP42006 in people with focal seizures - Part A. ClinicalTrial.gov Identifier: NCT02369471. Available from: https://clinicaltrials.gov/ct2/show/NCT02369471?term=cannabidivarin&draw=2&rank=5. Accessed 1029, 2019.
   Google Scholar
• Bialer M, Johannessen SI, Koepp MJ, et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia. 2018;59(10):1811–1841. doi:10.1111/epi.1455730368792
   PubMed Web of Science ®Google Scholar
• GW Research Ltd. A study of GWP42006 in people with focal seizures - part B. ClinicalTrial.gov Identifier: NCT02365610. Available from: https://clinicaltrials.gov/ct2/show/NCT02365610?term=cannabidivarin&draw=2&rank=6. Accessed 1029, 2019.
   Google Scholar
• GW Pharmaceuticals. GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006. Accessed 221, 2018.
   Google Scholar
• Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759. doi:10.3389/fneur.2018.0075930258398
   PubMed Web of Science ®Google Scholar
• Detyniecki K, Hirsch LJ. Cannabidiol for epilepsy: trying to see through the haze. Lancet Neurol. 2016;15(3):235–237. doi:10.1016/S1474-4422(16)00002-826776916
   PubMed Web of Science ®Google Scholar
• Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: no “strain,” no gain. Front Plant Sci. 2019;9:1969. doi:10.3389/fpls.2018.0196930687364
   PubMed Web of Science ®Google Scholar
• Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x21749363
   PubMed Web of Science ®Google Scholar
• Hill TD, Cascio MG, Romano B, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679–692. doi:10.1111/bph.1232123902406
   PubMed Web of Science ®Google Scholar